The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor.
SERINC3 (serine incorporator 3) and SERINC5 are recently identified host cell inhibitors of HIV-1 particle infectivity that are counteracted by the viral pathogenesis factor Nef. Here we confirm that HIV-1 Nef, but not HIV-1 Vpu, antagonizes the particle infectivity restriction of SERINC5. SERINC5 antagonism occurred in parallel with other Nef activities, including cell surface receptor downregulation, trans-Golgi network targeting of Lck, and inhibition of host cell actin dynamics. Interaction motifs with host cell endocytic machinery and the Nef-associated kinase complex, as well as CD4 cytoplasmic tail/HIV-1 protease, were identified as essential Nef determinants for SERINC5 antagonism. Characterization of antagonism-deficient Nef mutants revealed that counteraction of SERINC5 occurs in the absence of retargeting of the restriction factor to intracellular compartments and reduction of SERINC5 cell surface density is insufficient for antagonism. Consistent with virion incorporation of SERINC5 being a prerequisite for its antiviral activity, the infectivity of HIV-1 particles produced in the absence of a SERINC5 antagonist decreased with increasing amounts of virion SERINC5. At low levels of SERINC5 expression, enhancement of virion infectivity by Nef was associated with reduced virion incorporation of SERINC5 and antagonism-defective Nef mutants failed to exclude SERINC5 from virions. However, at elevated levels of SERINC5 expression, Nef maintained infectious HIV particles, despite significant virion incorporation of the restriction factor. These results suggest that in addition to virion exclusion, Nef employs a cryptic mechanism to antagonize virion-associated SERINC5. The involvement of common determinants suggests that the antagonism of Nef to SERINC5 and the downregulation of cell surface CD4 by Nef involve related molecular mechanisms.


OBJECTIVE
HIV-1 Nef critically determines virus spread and disease progression in infected individuals by incompletely defined mechanisms. SERINC3 and SERINC5 were recently identified as potent inhibitors of HIV particle infectivity whose antiviral activity is antagonized by HIV-1 Nef. To address the mechanism of SERINC5 antagonism, we identified four molecular determinants of Nef antagonism that are all linked to the mechanism by which Nef downregulates cell surface CD4. Functional characterization of these mutants revealed that endosomal targeting and cell surface downregulation of SERINC5 are dispensable and insufficient for antagonism, respectively. In contrast, virion exclusion and antagonism of SERINC5 were correlated; however, Nef was also able to enhance the infectivity of virions that incorporated robust levels of SERINC5. These results suggest that the antagonism of HIV-1 Nef to SERINC5 restriction of virion infectivity is mediated by a dual mechanism that is related to CD4 downregulation.
Department of Infectious Diseases, Integrative Virology, University Hospital Heidelberg, Heidelberg, Germany.
Birthe
B
Trautz
Department of Infectious Diseases, Integrative Virology, University Hospital Heidelberg, Heidelberg, Germany.
Virginia
V
Pierini
Department of Infectious Diseases, Integrative Virology, University Hospital Heidelberg, Heidelberg, Germany.
Rebecka
R
Wombacher
Department of Infectious Diseases, Integrative Virology, University Hospital Heidelberg, Heidelberg, Germany.
Bettina
B
Stolp
Department of Infectious Diseases, Integrative Virology, University Hospital Heidelberg, Heidelberg, Germany.
Amanda J
AJ
Chase
University of Trento, Centre for Integrative Biology, Trento, Italy.
Massimo
M
Pizzato
Department of Infectious Diseases, Integrative Virology, University Hospital Heidelberg, Heidelberg, Germany oliver.fackler@med.uni-heidelberg.de.
Oliver T
OT
Fackler
D015704:CD4 Antigens / Q000378:metabolism; D015536:Down-Regulation; D005814:Genes, Viral; D015658:HIV Infections / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000235:genetics / Q000472:pathogenicity* / Q000502:physiology*; D054884:Host-Pathogen Interactions / Q000235:genetics / Q000276:immunology / Q000502:physiology; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics / Q000502:physiology*; D009154:Mutation; D014771:Virion / Q000235:genetics / Q000502:physiology; D014774:Virulence / Q000235:genetics / Q000502:physiology; D054311:nef Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000502:physiology*
D015704:CD4 Antigens; D008565:Membrane Proteins; C000602387:SERINC5 protein, human; D054311:nef Gene Products, Human Immunodeficiency Virus; C514837:nef protein, Human immunodeficiency virus 1
Cell Host Microbe. 2009 Sep 17;6(3):218-30
19748464
Virology. 2012 Mar 1;424(1):33-44
22222210
N Engl J Med. 1995 Jan 26;332(4):228-32
7808489
J Biol Chem. 2002 Nov 29;277(48):46079-84
12354773
J Virol. 2014 Mar;88(6):3443-54
24403584
Nature. 1998 Jan 22;391(6665):397-401
9450757
J Virol. 2009 Jan;83(2):1093-104
18987145
J Biol Chem. 2002 Aug 9;277(32):28521-9
12032142
J Virol. 2015 Mar;89(6):3247-55
25568205
J Biol Chem. 2014 May 16;289(20):14030-44
24706755
Nature. 2015 Oct 8;526(7572):218-23
26416733
J Virol. 1999 Mar;73(3):1964-73
9971776
J Biol Chem. 2005 Oct 21;280(42):35776-83
16120614
Retrovirology. 2012 Apr 27;9:34
22537596
Virology. 1998 Oct 25;250(2):273-82
9792838
Cell Commun Signal. 2012 Dec 10;10(1):39
23227982
Virology. 2006 Nov 25;355(2):175-91
16916529
J Virol. 2010 Apr;84(8):3935-48
20147394
Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8167-72
10393966
Cell. 2006 Jun 16;125(6):1055-67
16777597
Elife. 2014;3:e01754
24473078
J Virol. 2005 Feb;79(3):1655-65
15650191
J Virol. 2012 Apr;86(8):4496-504
22301152
Cell Host Microbe. 2015 Oct 14;18(4):409-23
26439863
Virology. 2008 Apr 10;373(2):287-97
18191978
Nature. 2015 Oct 8;526(7572):212-7
26416734
J Exp Med. 1993 Jun 1;177(6):1561-6
8098729
Immunity. 2006 May;24(5):547-61
16713973
J Virol. 2014 Dec;88(24):14241-57
25275127
J Virol. 2008 Mar;82(6):2918-29
18094167
J Virol. 1994 May;68(5):2906-14
8151761
J Virol. 1995 Aug;69(8):5048-56
7541845
Cell Rep. 2015 Feb 3;10(4):586-99
25620704
J Virol. 2009 Nov;83(22):11528-39
19726522
Cell Microbiol. 2013 Oct;15(10):1605-21
23601552
PLoS One. 2007 Nov 21;2(11):e1212
18030346
Cell. 1991 May 17;65(4):651-62
2032289
J Biol Chem. 2004 Sep 17;279(38):39520-31
15258149
J Virol Methods. 2009 Mar;156(1-2):1-7
19022294
Virology. 2006 Aug 1;351(2):322-39
16684552
PLoS Biol. 2004 Jan;2(1):E6
14737186
Curr Biol. 2005 Apr 26;15(8):714-23
15854903
Curr Biol. 1998 Nov 5;8(22):1239-42
9811611
Science. 1995 Nov 10;270(5238):988-91
7481804
Cell. 1994 Mar 11;76(5):853-64
8124721
J Virol. 1996 Dec;70(12):9051-4
8971042
Immunity. 1998 May;8(5):647-56
9620685
Curr Biol. 1998 Nov 5;8(22):1235-8
9811606
Traffic. 2007 Jan;8(1):61-76
17140399
Front Microbiol. 2014 May 20;5:232
24904546
J Virol. 2008 Feb;82(3):1166-74
18032517
J Biol Chem. 2006 Jul 14;281(28):19618-30
16687395
Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11229-34
9736718
Cell Rep. 2013 Nov 14;5(3):802-12
24209751
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6812-7
17412836
Viruses. 2015 Dec 19;7(12):6730-8
26703715
J Virol. 1995 Jul;69(7):4053-9
7539505
Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18541-6
23093676
Cell Host Microbe. 2009 Aug 20;6(2):174-86
19683683
J Virol. 2007 Apr;81(8):3877-90
17267500
Immunity. 1997 Mar;6(3):283-91
9075929
Blood. 2012 Jan 19;119(3):786-97
22123847
J Immunol. 2012 Aug 15;189(4):1898-910
22802418